Skip To Main Content
Aline Barth on Muck Rack

Aline Barth

As seen in: Nature, Wiley Online Library
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Aline

Contact Aline, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Publisher Correction: Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial

|
By Julio Rosenstock, Ildiko Lingvay, Donna Ryan, Ania M. Jastreboff, Robert F. Kushner, Andres Acosta, Thomas C. Blevins, Timothy Smith, Lisa Connery, Yao Li, Mike Liu, Aline Barth, Jamie Butcher, Antonio Civitarese, Huibin Yue, Blai Coll
| Nature Verified
Correction to: Nature Medicine https://doi.org/10.1038/s41591-026-04476-6, published online 5 June 2026. In the version of the article initially published, in Fig. 3b, the Aleniglipron 120 mg column initially listed LS mean change as “–12.1” and has been updated to read “–12.7,” while in Fig. 4, the data was missing from the bottom-right panel, and all arrows were missing from the “Vomiting” panels. Figures 3 and 4 have now been corrected in the HTML and PDF versions of the article.
Open in Who Shared Issue with article?

Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial

|
By Julio Rosenstock, Ildiko Lingvay, Donna Ryan, Ania M. Jastreboff, Robert F. Kushner, Andres Acosta, Thomas C. Blevins, Timothy Smith, Lisa Connery, Yao Li, Mike Liu, Aline Barth, Jamie Butcher, Antonio Civitarese, Huibin Yue, Blai Coll
| Nature Verified
Abstract Aleniglipron is an oral, small-molecule glucagon-like peptide-1 receptor agonist (GLP1-RA) in development for obesity treatment. The ACCESS phase 2b placebo-controlled, double-blind study randomized 230 adults (mean BMI 39.5 kg m−2, 54% female) with obesity or overweight to examine the effects of once-daily aleniglipron escalated every 4 weeks to 45, 90 or 120 mg.
Open in Who Shared Issue with article?

Artificial Intelligence: From Buzzword to Useful Tool in Clinical Pharmacology

|
By Mohamed Shahin, Pfizer Inc. USA, Aline Barth, Jagdeep T. Podichetty
| Wiley Online Library Verified
Supporting Information Filename Description cpt3083-sup-0001-Supinfo.docxWord 2007 document , 127.7 KB Supplementary file
Open in Who Shared View Duplicates (8) Issue with article?
See all 3 articles